---
title: "Dupixent (dupilumab) in atopic dermatitis: Drug interactions questions"
description: "Drug interactions questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Dupixent have drug interactions? 1 question quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Drug interactions questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## Drug interactions

<a id="dupixent-drug-interactions"></a>

### Does Dupixent have drug interactions?

> “DUPIXENT is not metabolized through the liver or excreted through the kidneys<sup>1</sup>
> No known drug-to-drug interactions<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Mechanism of Action for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action#:~:text=DUPIXENT%20is%20not%20metabolized%20through,No%20known%20drug%2Dto%2Ddrug)

> “Drug Interaction Studies 
> An effect of dupilumab on the PK of co-administered medications is not expected. Based on the 
> population analysis, commonly co-administered medications had no effect on DUPIXENT 
> pharmacokinetics in subjects with moderate-to-severe asthma. 
> Cytochrome P450 Substrates 
> The effects of dupilumab on the pharmacokinetics of midazolam (metabolized by CYP3A4), 
> warfarin (metabolized by CYP2C9), omeprazole (metabolized by CYP2C19), metoprolol 
> (metabolized by CYP2D6), and caffeine (metabolized by CYP1A2) were evaluated in a study 
> with 12-13 evaluable subjects with AD (a SC loading dose of 600 mg followed by 300 mg SC 
> weekly for six weeks). No clinically significant changes in AUC were observed. The largest 
> effect was observed for metoprolol (CYP2D6) with an increase in AUC of 29%.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 35, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=35)

> “Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Vaccinations%3A%20Consider%20completing%20all%20age%2Dappropriate,vaccines%20during%20treatment%20with%20DUPIXENT.)

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Indication](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
